

**FOLEY
HOAG**
ATTORNEYS AT LAW



August 31, 2001

Assistant Commissioner of Patents
Washington, DC 20231

RECEIVED

SEP 07 2001

TECH CENTER 1600/2900

James T. Olesen, Ph.D.
Boston Office
617.832.1764
jto@foleyhoag.com



Re: U.S. Patent Application No: 09/845,129
Entitled: *Diagnostics and Therapeutics for diseases Associated with an
IL-1 Inflammatory Haplotype*
Filed: April 27, 2001; By: Duff et al.
Group Art Unit: 1655
Atty Ref: MSA-010.03

Dear Sir:

Enclosed please find the following documents submitted by the Applicants in the
above-referenced application:

1. Copy of the Notice to Comply with Requirements for Patent Applications
Containing Nucleotide Sequence and/or Amino Acid Sequence
Disclosures;
2. Statement Under 37 C.F.R. § 1.821(e), (f), and (g);
3. Paper Copy of Sequence Listing Previously Submitted in Parent
Application Serial No. 09/345,217 (altered with current serial number and
date); and
4. Return receipt postcard.

The Commissioner is hereby authorized to charge any under-payments or credit
any over-payments to our Deposit Account No. 06-1448.

<p align="center">Certificate of First Class Mailing</p> <p>I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail with sufficient postage in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on the date set forth below:</p> <p><u>August 31, 2001</u> Date</p> <p> William Botting</p>	<p>Respectfully submitted, FOLEY, HOAG & ELIOT LLP</p> <p></p> <p>James T. Olesen, Ph.D. Reg. No. 46,967 Agent for Applicants Customer ID No. 25181</p>
---	---

20/470467.1

BOSTON / One Post Office Square / Boston, Massachusetts 02109 / TEL: 617.832.1000 / FAX: 617.832.7000
WASHINGTON, DC / 1747 Pennsylvania Ave., NW / Suite 1200 / Washington, DC 20006 / TEL: 202.223.1200 / FAX: 202.785.6687
Foley, Hoag & Eliot LLP www.foleyhoag.com

SEP 07 2001



UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/845,129	04/27/2001	Gordon W. Duff	MSA-010.03

25181
FOLEY, HOAG & ELIOT, LLP
PATENT GROUP
ONE POST OFFICE SQUARE
BOSTON, MA 02109CONFIRMATION NO. 1917
FORMALITIES
LETTER
"OC000000006253356"

Date Mailed: 07/03/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE